1. Home
  2. RXRX vs DMRA Comparison

RXRX vs DMRA Comparison

Compare RXRX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Recursion Pharmaceuticals Inc.

RXRX

Recursion Pharmaceuticals Inc.

HOLD

Current Price

$3.82

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$20.29

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RXRX
DMRA
Founded
2013
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
RXRX
DMRA
Price
$3.82
$20.29
Analyst Decision
Buy
Buy
Analyst Count
4
2
Target Price
$7.50
★ $43.00
AVG Volume (30 Days)
★ 17.2M
625.3K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
14.79
★ 121.48
EPS
★ N/A
N/A
Revenue
★ $74,681,000.00
N/A
Revenue This Year
$12.11
N/A
Revenue Next Year
$82.52
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 26.92
N/A
52 Week Low
$2.77
$16.50
52 Week High
$7.18
$34.89

Technical Indicators

Market Signals
Indicator
RXRX
DMRA
Relative Strength Index (RSI) 57.52 28.36
Support Level $2.90 $18.59
Resistance Level $4.05 $26.76
Average True Range (ATR) 0.24 1.73
MACD 0.03 -0.44
Stochastic Oscillator 69.16 10.42

Price Performance

Historical Comparison
RXRX
DMRA

About RXRX Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: